Avelumab Produces Durable Responses in Metastatic Merkel Cell Carcinoma

Video

In this video we discuss promising results of the anti–PD-L1 agent avelumab in patients with metastatic Merkel cell carcinoma who had previously been treated with chemotherapy.

The phase II JAVELIN Merkel 200 trial found that the anti–PD-L1 agent avelumab produced durable responses in patients with metastatic Merkel cell carcinoma who had previously been treated with chemotherapy, according to data presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held earlier this month in Chicago (abstract 9508).

In this video, Howard L. Kaufman, MD, of the Rutgers Cancer Institute of New Jersey, discusses these results.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.